

Gut Microbiome and Adjuvant Treatment of COVID-19

Subjects: Virology | Infectious Diseases

Submitted by:  Kai Hilpert

Definition

High expression of the transmembrane protein angiotensin I converting enzyme 2 (ACE2), more than 100-times higher as in the lung, and transmembrane serine protease 2 (TMPRSS2) in the gastrointestinal tract leads to infection with SARS-CoV-2. According to meta-analysis data, 9.8–20% of COVID-19 patients experience gastrointestinal symptoms, where diarrhoea is the most frequent, and about 50% shed viruses with high titre through their faeces, where a first faecal transmission was reported. Furthermore, gut inflammation, intestinal damage, and weakening of the gut mucosal integrity that leads to increased permeability has been shown in different studies for COVID-19 patients. This can lead to increased inflammation and bacteraemia. Low mucosal integrity combined with low intestinal damage is a good predictor for disease progression and submission to the intensive care unit (ICU). Several pilot studies have shown that the gut microbiome of COVID-19 patients is changed, microbial richness and diversity were lower, and opportunistic pathogens that can cause bacteraemia were enriched compared to a healthy control group. In a large proportion of these patients, dysbiosis was not resolved at discharge from the hospital and one study showed dysbiosis is still present after 3 months post COVID-19. Consequently, there might be a link between dysbiosis of the gut microbiome in COVID-19 patients and chronic COVID-19 syndrome (CCS). Various clinical trials are investigating the benefit of probiotics for acute COVID-19 patients, the majority of which have not reported results yet. However, two clinical trials have shown that a certain combination of probiotics is beneficial and safe for acute COVID-19 patients. Mortality was 11% for the probiotic treatment group, and 22% for the control group. Furthermore, for the probiotic group, symptoms cleared faster, and an 8-fold decreased risk of developing a respiratory failure was calculated. In conclusion, evidence is arising that inflammation, increased permeability, and microbiome dysbiosis in the gut occur in COVID-19 patients and thus provide new targets for adjuvant treatments of acute and chronic COVID-19. More research in this area is needed.

1. Gastrointestinal Symptoms Caused by SARS-CoV-2

SARS-CoV-2 is an RNA virus that belongs to the genera Betacoronavirus ^[1]. Coronaviruses (CoVs) are known for causing respiratory and gastrointestinal diseases in animals and humans. Young piglets are often infected by porcine epidemic diarrhoea virus (PEDV) or porcine transmissible gastroenteritis virus (TGEV), causing acute diarrhoea, vomiting, and dehydration ^[2]. PEDV and TEV show about 100% morbidity and 50–100% mortality ^{[3][4]}. In cows, the bovine coronavirus (betacoronavirus) causes pneumonia and diarrhoea in calves and adult cows ^[5]. In humans, 15–30% of the respiratory tract infections each year are caused by the CoVs 229E, OC43, NL63, and HKU1 ^{[6][7]}.

SARS-CoV-2 induces gastrointestinal symptoms in 9.8–20% of hospitalized patients, according to several meta-analyses of COVID-19 patients; see **Table 1**. Most studies show diarrhoea as the main syndrome, followed by nausea/vomiting and a lower frequency of abdominal pain. Anorexia varies very widely between studies, from 1 to 79% ^[8]. It is difficult to judge to what percentage of these reported symptoms is indeed a direct consequence of the SARS-CoV-2 infection in the gut. The virus can influence the vagus nerve and also create a cytokine storm that can cause nausea and diarrhoea ^[9]. Some studies report symptoms after hospitalization and therefore the use of antibiotics, antivirals, enteral feeding, proton pump inhibitors, and other medications can cause gastrointestinal symptoms as well.

Table 1. Overview of six meta-analyses of COVID-19 patient studies and their reported gastrointestinal symptoms.

Number of COVID-19 Patients	Gastro-Intestinal Symptoms	Diarrhoea	Nausea/Vomiting	Abdominal Pain	Number of Studies Used in Meta-Analysis	Reference
2477	13%	7.8%	5.5%	2.7%	17	[10]
4243	17.6%	12.5%	10.2%	9.2%	60	[11]
4805	Not reported	7.4%	4.6%	Not reported	29	[12]
5601	9.8%	10.4%	7.7%	6.9%	37	[13]
17,776	20%	13%	8%	4%	108	[14]
18,246	Not reported	11.5%	6.3%	2.3%	43	[15]

Two studies showed that there were no significant differences observed in critical care patients vs non-severe patients in regards to their gastrointestinal symptoms [16][17][18]. The opposite observations were reported by Wang et al., showing statistical differences in the gastrointestinal symptoms (anorexia and abdominal pain) between ICU patients and non-ICU patients, where ICU patients had a higher percentage of these symptoms [19]. In general, the studies are often difficult to compare, since various parameters were used, for example, the type of symptoms reported, symptoms reported at the onset of illness, or during the hospital stay. It remains to be seen if there are regional differences or differences concerning the SARS-CoV-2 strains.

2. Expression of ACE2 and TMPRSS2 in the Gastrointestinal Tract

The virus SARS-CoV-2 enters human cells via the transmembrane protein angiotensin I converting enzyme 2 (ACE2) as a receptor. In addition, host proteases are required to prime the spike protein, especially transmembrane serine protease 2 (TMPRSS2) [20]. ACE2 is highly expressed in the small intestine, colon, and duodenum, compared to very little expression in the lung; see **Figure 1** [21]. Immunohistochemistry on human tissue confirms the data, showing high expression of ACE2 protein in the gastrointestinal tract but minimal expression in the lung [22][21].




Figure 1. Expression of the angiotensin I converting enzyme 2 (ACE2) in different human organs, based on data by Hikmet et al. [21]. The expression of ACE2 was determined by transcriptomics by three different independent consortia.

Using RNAseq, the expression of TMPRSS2 was determined to be high in the small intestine, colon, stomach, and oesophagus; however, it was also high in the lungs [23]. Co-expression of the cell receptor ACE II (ACE2) and the transmembrane serine protease 2 (TMPRSS2) in oesophageal upper epithelial cells, glandular cells, and cells from the ileum and colon was confirmed by single-cell transcriptomic analysis [24]. Given the high expression levels of both ACE2 and TMPRSS2 in the gastrointestinal tract, it seems surprising that

gastrointestinal symptoms are relatively mild and low in occurrence.

3. Gut Inflammation in COVID-19 Patients

In a small study describing 40 COVID-19 patients, where 18 reported no diarrhoea, 13 where diarrhoea had ceased, and 9 with active diarrhoea [25], the group with diarrhoea, especially the active diarrhoea, showed a strong increase in faecal calprotectin concentration, a marker for inflammation. This increase correlated with serum interleukin-6 (IL-6) concentration but not C-reactive protein (CRP) or ferritin. These results were underpinned by a study with 26 patients by Reuken et al. [26]. Both studies indicate that inflammation in the gut may occur in COVID-19 patients with diarrhoea and/or positive rectal swabs/faeces.

The influence of COVID-19 on microbial translocation and intestinal damage was investigated [27]. Microbial translocation is the ability of microbes or their products to translocate across the normally very tight epithelial layer into the extraintestinal space and systemic circulation. It occurs when the gut mucosal integrity is weakened. Oliva et al. used three different blood markers to measure microbial translocation and intestinal damage (lipopolysaccharide binding protein, EndoCab IgM, and intestinal fatty acid binding protein) [27]. The cohort was comprised of 45 COVID-19 patients, where 46.6% were admitted to ICU. The data were compared to a healthy donor group. Blood samples taken from day 0 and day 7 showed that COVID-19 patients had both higher microbial translocation and intestinal damage that was maintained over the 7 days. Patients with more severe symptoms showed higher microbial translocation but low intestinal damage compared to patients with mild symptoms. This pattern was a good predictor of disease progression and submission to the ICU. A different study (not yet reviewed) provides the same conclusions. In the 16 COVID-19 patients investigated, the mean levels of lipopolysaccharide (LPS), peptidoglycan (PGN), and fatty acid-binding protein-2 (FABP2) were all increased by about 2 fold compared to healthy controls [28]. All three markers indicate increased gut permeability, and the authors concluded that it may be a source of inflammation, bacteriemia, and consequently worsening of the disease.

4. SARS-CoV-2 and the Gut Microbiome

It has been shown that SARS-CoV-2 infection alters the microbiome of the lung and leads to reduced diversity and in some cases to community collapse [29], shows different bacterial diversity and fewer commensals compared to non-COVID-19 pneumonia [30], and on a functional analysis “decreased potential for lipid metabolism and glycan biosynthesis and metabolism pathways, and increased potential for carbohydrate metabolism pathways” [31]. There is crosstalk between the gut and the lung, often referred to as the “gut-lung axis”. This crosstalk is bidirectional, and the effects of the microbiome in chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) has been studied [32]. For a review on the lung-gut axis in respiratory diseases, see Dumas et al. [33]. Infection with SARS-CoV-2 and consequently inflammation in the lung could also lead to changes in the gut microbiota that can further drive the inflammation response. In addition, SARS-CoV-2 infections in the gastrointestinal tract could lead to further changes in the microbiome. It is speculated that the composition and diversity of the “pre-infection” microbiome and post-infection changes, and crosstalk of the gut and lung microbiome could influence the outcome of clinical manifestation [34][35]. In principle, “optimizing” the gut microbiome, especially in the elderly or people with diabetes type II, could positively affect the outcome of SARS-CoV-2 infections.

Honarmand Ebrahimi performed bioinformatic analysis and concluded that members of the microbiome (especially Proteobacteria) of the upper respiratory tract produce ACE2 homologues as well as homologues of TMPRSS2. These could reduce the infectivity of SARS-CoV-2 since the virus would bind to bacteria instead of lung cells. Proteobacteria are reduced in the elderly and will therefore provide less protection [36]. Proteobacteria are also part of the human gut microbiome, but whether the same effect occurs in this more complex environment is unclear. In addition, infection will already occur in the upper gastrointestinal tract where a very different microbiome exists compared to the lower part. Similar to the lung microbiome, diversity in the gut microbiome decreases with age and protective effects may be reduced in the elderly.

The first pilot studies of the gut microbiome of COVID-19 patients have been performed, and examples are given in **Table 3**. These small studies have their limitations; however, they all have shown for the majority of patients that dysbiosis caused by COVID-19 was not resolved after COVID-19 symptoms eased and patients

were discharged. Treatment with antibiotics can also change the gut microbiota; however, in some studies, the described changes in the microbiome were independent of antibiotic treatment. There are various descriptions of dysbiosis. For example, according to [37], “dysbiosis is any change to the composition of resident commensal communities relative to the community found in healthy individuals” and according to [38], “Dysbiosis (also called dysbacteriosis) is characterized as a disruption to the microbiota homeostasis caused by an imbalance in the microflora, changes in their functional composition and metabolic activities, or a shift in their local distribution”. The changes that cause dysbiosis in the microbiome seem to be specific to COVID-19 and can be used as predictors of disease severity. Larger and more systematic studies are urgently needed to understand the impact of SARS-CoV-2 on the gut microbiome, especially long-term effects.

Table 3. Examples of pilot studies investigating the changes in the gut microbiome in COVID-19 patients.

Number of COVID-19 Patients	Healthy Control	Age (Median)		Microbiome Investigated	Enrichment	Loss	Reference
		COVID-19	Control				
15	15 (6 with community-acquired pneumonia)	55	48 (50 for Pneumonia)	Gut (faecal sample)	opportunistic pathogens that can cause bacteraemia, including <i>Clostridium hathewayi</i> , <i>Actinomyces viscosus</i> , and <i>Bacteroides nordii</i>	Commensals decreased, for example, <i>Eubacterium faecalis</i> , <i>Faecalibacterium prausnitzii</i> , <i>Roseburia</i> , and <i>Lachnospiraceae</i> taxa 1*	[39]
30	30 (24 with H1N1)	55	53.5 (48.5 for H1N1)	Gut (faecal sample)	<i>Streptococcus</i> , <i>Rothia</i> , <i>Veillonella</i> , <i>Erysipelatoclostridium</i> , and <i>Actinomyces</i>	mean community richness and microbial diversity were significantly lower in COVID-19 and H1N1 patients 2*	[40]
30	30	46	34	Gut (faecal sample)	Diversity 2.5-fold higher, for example, <i>Candida albicans</i> , <i>Candida auris</i> , and <i>Aspergillus flavus</i>		[41]
24	48	49	48	Oral cavity and gut (saliva and faecal sample)	Lipopolysaccharide producing bacteria increased	Microbial diversity decreased, butyric acid-producing bacteria decreased	[42]
14	16	63.3	40.5	Plasma (from blood)	65% of COVID-19 patients showed atypical plasma microbiome 3*		[28]

1* Antibiotic treatment led to further depletion of multiple symbionts beneficial to host immunity, including *Faecalibacterium prausnitzii*, *Lachnospiraceae* bacterium 5_1_63FAA, *Eubacterium rectale*, *Ruminococcus obeum*, and *Dorea formicigenerans*. 2* for COVID-19 patients loss of *Ruminococcaceae* family and several genera from the *Lachnospiraceae* family (*Fusicatenibacter*, *Anaerostipes*, *Agathobacter*, unclassified *Lachnospiraceae*, and *Eubacterium hallii* group). 3* abundance of Gram-negative bacteria.

Gou et al. discovered blood proteomic biomarkers that can predict the severity of COVID-19 [43]. Gut microbial

features like the relative abundance of *Bacteroides* genus, *Streptococcus* genus, *Lactobacillus* genus, Ruminococcaceae family, Lachnospiraceae family, and Clostridiales order will drive these biomarkers. The faecal metabolome was investigated and showed that 45 faecal metabolites, mainly within the categories of amino acids, fatty acids, and bile acids, can provide a link between the identified core gut microbiota, inflammation, and COVID-19 susceptibility.

5. Targeting the Gut Microbiome as Adjunctive Therapy for COVID-19

The gastrointestinal tract does not just have a digestive function but is also responsible for achieving immune system homeostasis. The gut-associated lymphoid tissue harbours about 70% of the entire immune system [44]. The gut microbiome, its metabolites, and miRNAs influence this homeostasis and also impact mucosal integrity. Weakening of this integrity can result in further inflammation and bacteraemia. As described above, COVID-19 leads to dysbiosis of the gut microbiome, gut inflammation, and weakening of mucosal integrity.

According to the Food and Agriculture Organization of the United Nations World Health Organization, probiotics are defined as “live microorganisms which when administered in adequate amounts confer a health benefit on the host.” Probiotics have been shown to enforce mucosal integrity [45] and be beneficial for influenza virus clearing [46]. Probiotics could therefore in theory support patients with COVID-19 to lessen inflammation, prevent/reduce the very dangerous cytokine storm, and support clearing of the virus. Several clinical trials are underway to study the impact of probiotics on COVID-19 as an adjunctive therapy.

A study from Italy [47] enrolled 70 COVID-19 patients with moderate symptoms (>37.5 °C fever, need of non-invasive oxygen therapy, and according to imaging more than 50% lung involvement) who were treated with hydroxychloroquine (HCQ) 200 mg twice a day, antibiotics (ABX) (azithromycin 500 mg), and Tocilizumab (TCZ), the dosage of which was 8 mg/kg (up to a maximum of 800 mg per dose) with an interval of 12 h two times. A group of randomly picked 28 patients (mean age 59) received probiotics as adjunctive therapy while the remaining 48 patients (mean age 60.5) formed the control group. In this study, Sivomixx® (SivoBiome®, Rockville, MD, USA) was used, consisting of *Streptococcus thermophilus* DSM 32345, *Lactobacillus acidophilus* DSM 32241, *Lactobacillus helveticus* DSM 32242, *Lactobacillus paracasei* DSM 32243, *Lactobacillus plantarum* DSM 32244, *Lactobacillus brevis* DSM 27961, *Bifidobacterium lactis* DSM 32246, and *Bifidobacterium lactis* DSM 32247. Patients received three equal doses per day (sum of 2400 billion bacteria), for 14 days. Diarrhoea was resolved for 92.9% of the patients in the probiotic group within three days, whereas in the control group, less than 10% after three days and only about 35% after 7 days. Other symptoms like fever, asthenia, headache, myalgia, and dyspnoea resolved in 100% of the patients after 7 days, but only in about 50% of the control group. The author stated, “After 7 days of treatment, the calculated model showed an 8-fold significantly decreased risk to evolve a respiratory failure” [47]. In the probiotic group, 0% of the patients were transferred to the ICU or had a lethal outcome, compared to 4.8% and 9.5%, respectively, in the control group.

The same probiotic Sivomixx® was used by the same group to enlarge the study [48]. This time, 200 patients were enrolled, where 88 received the probiotic at the same dose (3 times daily, a total of 2400 billion bacteria). A similar treatment was provided, including hydroxychloroquine (200 mg twice a day for 7 days), azithromycin (500 mg once a day for 7 days), lopinavir-ritonavir (400/100 mg twice a day), or darunavir-cobicistat (800/150 mg once a day) for 14 days. The risk to be transferred to the ICU was similar in both the control, 21.4% (mean age 64), and probiotic treatment group, 18.1% (mean age 62). There was a significant difference in the mortality between both groups, being 22% in the control group vs. 11% in the probiotic treatment group, clearly demonstrating the potential of this adjuvant treatment.

Currently, Sivomixx® is being tested in another clinical trial in Italy in conjunction with ozone therapy and the recommend best treatment [49]. Systemic autohemotherapy (twice a day) will be combined with 200 billion CFU/day of Sivomixx® (six sachets twice a day). An estimated 152 participants will be enrolled, and various outcome measures determined, with the primary outcome being the number of patients requiring orotracheal intubation.

A clinical trial in Mexico sponsored by AB Biotics, SA, has finished (May 2021), but no data have been published yet [50]. In this intervention study, 300 COVID-19 patients with mild symptoms were enrolled. To a

randomly selected group, a probiotic was given (Lactobacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485 y Pediococcus acidilactici CECT 7483) once a day for 30 days. Various primary and secondary outcomes were determined, for example, severity progression, stay at ICU (frequency and length), mortality, and changes in the faecal microbiome.

A Canadian clinical trial has now finished (June 2021) as well, but no data have been published yet [51]. Nasal irrigation with Probiolinse (2.4 billion colony forming units (CFU) of Lactococcus Lactis W136, (NPN: 80085895)) twice daily for 14 days was used as an intervention. A total of 23 COVID-19 patients were enrolled and changes in severity were monitored for up to 28 days. Another Canadian clinical trial monitored the duration of symptoms, severity, and changes in the oral and faecal microbiome of an estimated 84 patients [52]. A probiotic (undefined) was given to the treatment group for 25 days.

An interventional multi-centre clinical study in Spain is evaluating the probiotic Lactobacillus Coryniformis K8, using a dose of 3×10^9 CFU/day for 2 months, on health care workers [53]. The estimated enrolment is 314 participants, and the incidence and severity of COVID-19 will be measured. In the United States at Duke University, a study is being performed looking at the microbiome of exposed household members from COVID-19 patients. The intervention will be made by providing a probiotic consisting of Lactobacillus rhamnosus GG. In total, 182 participants are expected to enrol [54][55]. A clinical trial in Austria aims to use Omni-Biotic® 10 AAD (Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, and Lactobacillus salivarius W24) as an intervention for COVID-19-related diarrhoea [56]. It is planned that an estimated 120 patients will be enrolled.

Another way to influence the gut microbiome more radically is faecal microbiota transplant (FMT). Two cases were reported, from an 80- and a 19-year-old man, who received an FMT to treat a Clostridioides difficile infection (CDI) [57]. Both had severe comorbidities. Unknowingly, both were at the onset of developing COVID-19 at the time point of the FMT. Despite the risk factors of both patients in developing severe COVID-19 symptoms, both experienced rather mild symptoms. This gave rise to a hypothesis that FMT can be used to reduce the risk of severe illness progression. A clinical trial was started to investigate this hypothesis [58].

6. Is There a Link between Changes in the Gut Microbiome in COVID-19 Patients and Chronic COVID-19 Symptoms?

Evidence is accumulating that the gut microbiome is changing for COVID-19 patients and as described above, in a large proportion of patients, these changes (dysbiosis) seem to last. There is compelling evidence that gut microbial dysbiosis can lead to or drive various health problems and is associated with a lower quality of life. It might be no coincidence that more reports are being published describing the long-term effects of COVID-19. Lopez-Leon et al. showed in a meta-analysis that about 80% of COVID-19 patients developed at least one symptom [59]. The main symptoms of this chronic COVID-19 syndrome (CCS) (1) were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnoea (24%); however, joint pain, sleeping problems, depression, and diarrhoea were reported as well. Fatigue, headache, attention disorders, joint pain, headaches, sleeping problems, depression, and diarrhoea have been linked to dysbiosis in the gut microbiome [60][61][62][63][64][65][66][67][68]. There seems to be an intriguing overlap between these symptoms and more research in this area might reveal new treatment options for CCS. For a more detailed discussion, see [69]. A not yet peer-reviewed article (MedRxiv) shows a loss of diversity in the gut microbiome in chronic COVID-19 patients who experienced severe acute COVID-19 symptoms [70], underpinning the importance of studying this potential connection between gut dysbiosis and chronic COVID-19.

7. Conclusions

SARS-CoV-2 is infecting the gut in a portion of COVID-19 patients, as about 20% develop gastrointestinal symptoms, and about 50% test positive using faecal samples or anal swabs. ACE2 and TMPRSS2 are highly expressed in the gut and explain the reproduction of viruses there. The first studies have shown that the lung, oral, as well as the gut microbiome changes in COVID-19 patients and for a large proportion of patients, the changes do not resolve after discharge from the hospital. Since the gut is also a place to maintain

immune homeostasis, changes in the gut can cause or accelerate an inflammation response, weakening of mucosal stability, and a cytokine storm, as seen in critically ill patients. Therefore, it was hypothesized that probiotics or other interventions to favourably change the microbiome or address increased permeability in the gut could reduce the immune answer and be beneficial for the COVID-19 patient. Two clinical trials have now shown the benefits of probiotics, reducing the time to symptom clearing, reducing mortality, and decreasing the risk of developing respiratory failure by 8-fold. Several other clinical trials are underway and will give more insight into the benefits. There also might be a link between changes in the gut microbiome and chronic COVID-19 syndrome (CCS). More research is needed to investigate the potential of this adjuvant treatment.

References

1. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. In *Coronaviruses Methods and Protocols*; Springer: New York, NY, USA, 2015; pp. 1–23.
2. Wood, E.N. An apparently new syndrome of porcine epidemic diarrhoea. *Veter. Rec.* 1977, 100, 243–244.
3. Jung, K.; Annamalai, T.; Lu, Z.; Saif, L.J. Comparative pathogenesis of US porcine epidemic diarrhea virus (PEDV) strain PC21A in conventional 9-day-old nursing piglets vs. 26-day-old weaned pigs. *Veter. Microbiol.* 2015, 178, 31–40.
4. Saif, L.J.; Wang, Q.; Vlasova, A.N.; Jung, K.; Xiao, S. Coronaviruses. In *Diseases of Swine*; Wiley: Hoboken, NJ, USA, 2019; pp. 488–523.
5. Okur, G.S.; Yazici, Z.; Albayrak, H.; Meral, Y. Rotavirus and Coronavirus Prevalances in Healthy Calves and Calves with Diarrhoea. Available online: <https://www.researchgate.net/publication/287890228> (accessed on 29 April 2020).
6. Rehman, S.U.; Shafique, L.; Ihsan, A.; Liu, Q. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. *Pathogens* 2020, 9, 240. Available online: <https://www.mdpi.com/2076-0817/9/3/240> (accessed on 28 April 2020).
7. Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A.C.K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol.* 2016, 24, 490–502.
8. Chen, Z.-R.; Liu, J.; Liao, Z.-G.; Zhou, J.; Peng, H.-W.; Gong, F.; Hu, J.-F.; Zhou, Y. COVID-19 and gastroenteric manifestations. *World J. Clin. Cases* 2021, 9, 4990–4997.
9. Perisetti, A.; Goyal, H.; Gajendran, M.; Boregowda, U.; Mann, R.; Sharma, N. Prevalence, mechanisms, and implications of gastrointestinal symptoms in COVID-19. *Front. Med.* 2020, 7, 588711.
10. Kumar, V.C.S.; Mukherjee, S.; Harne, P.S.; Subedi, A.; Ganapathy, M.K.; Patthipati, V.S.; Sapkota, B. Novelty in the gut: A systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. *BMJ Open Gastroenterol.* 2020, 7, 417. Available online: <http://bmjopengastro.bmj.com/> (accessed on 5 October 2020).
11. Cheung, K.S.; Hung, I.F.; Chan, P.P.; Lung, K.C.; Tso, E.; Liu, R.; Ng, Y.Y.; Chu, M.Y.; Chung, T.W.; Tam, A.R.; et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. *Gastroenterology* 2020, 159, 81–95.
12. Parasa, S.; Desai, M.; Chandrasekar, V.T.; Patel, H.K.; Kennedy, K.F.; Roesch, T.; Spadaccini, M.; Colombo, M.; Gabbiadini, R.; Artifon, E.L.; et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. *JAMA Netw. Open* 2020, 3, e2011335. Available online: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767009> (accessed on 27 August 2020).
13. Rokkas, T. Gastrointestinal involvement in COVID-19: A systematic review and meta-analysis. *Ann. Gastroenterol.* 2020, 33, 355–365.
14. Dorrell, R.D.; Dougherty, M.K.; Barash, E.L.; Lichtig, A.E.; Clayton, S.B.; Jensen, E.T. Gastrointestinal and hepatic manifestations of COVID-19: A systematic review and meta-analysis. *JGH Open* 2021, 5, 107–115.
15. Silva, F.A.F.D.; Brito, B.B.D.; Santos, M.L.C.; Marques, H.S.; Silva, R.T.D.; Carvalho, L.S.D.; Vieira, E.S.; Oliveira, M.V.; Melo, F.F.D. COVID-19 gastrointestinal manifestations: A systematic review. *Rev. Soc. Bras. Med. Trop.* 2020, 53, 1–11.
16. Fang, D.; Ma, J.; Guang, J.; Wang, M.; Song, Y.; Tian, D. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: A single-center, descriptive study. *Chin. J. Dig.* 2020, 40, E005.
17. Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-L.; Hui, D.S.; et al. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 2020, 382, 1708–1720.
18. Tian, Y.; Rong, L.; Nian, W.; He, Y. Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission. *Aliment. Pharmacol. Ther.* 2020, 51, 843–851.
19. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020, 323, 1061–1069.
20. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020, 181, 271–280. Available online: <https://pubmed.ncbi.nlm.nih.gov/32142651/> (accessed on 14 June 2021).
21. Hikmet, F.; Méar, L.; Edvinsson, Å.; Micke, P.; Uhlén, M.; Lindskog, C. The protein expression profile of ACE2 in human

tissues. *Mol. Syst. Biol.* 2020, 16, e9610.

22. Xiao, F.; Tang, M.; Zheng, X.; Liu, Y.; Li, X.; Shan, H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* 2020, 6, 1831–1833.
23. TMPRSS2 Gene—GeneCards. TMPS2 Protein TMPS2 Antibody. Available online: <https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMPRSS2> (accessed on 9 September 2021).
24. Zhang, H.; Kang, Z.; Gong, H.; Xu, D.; Wang, J.; Li, Z.; Li, Z.; Cui, X.; Xiao, J.; Zhan, J.; et al. Digestive system is a potential route of COVID-19: An analysis of single-cell coexpression pattern of key proteins in viral entry process. *Gut* 2020, 69, 1010–1018.
25. Effenberger, M.; Grabherr, F.; Mayr, L.; Schwaerzler, J.; Nairz, M.; Seifert, M.; Hilbe, R.; Seiwald, S.; Scholl-Buergi, S.; Fritsche, G.; et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. *Gut* 2020, 69, 1543–1544.
26. Reuken, P.A.; Wüst, M.; Löffler, B.; Bauer, M.; Stallmach, A. Letter: SARS-CoV-2-induced gastrointestinal inflammation. *Aliment. Pharmacol. Ther.* 2020, 52, 1748–1749. Available online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753696/pdf/APT-52-1750.pdf> (accessed on 14 June 2021).
27. Oliva, A.; Miele, M.C.; Di Timoteo, F.; De Angelis, M.; Mauro, V.; Aronica, R.; Al Ismail, D.; Ceccarelli, G.; Pinacchio, C.; D’Ettorre, G.; et al. Persistent systemic microbial translocation and intestinal damage during coronavirus disease-19. *Front. Immunol.* 2021, 12, 2810.
28. Prasad, R.; Patton, M.J.; Floyd, J.L.; Vieira, C.P.; Fortmann, S.; DuPont, M.; Harbour, A.; See, J.R.C.; Wright, J.; Lamendella, R.; et al. Plasma microbiome in COVID-19 subjects: An indicator of gut barrier defects and dysbiosis. *bioRxiv* 2021. Available online: <https://www.biorxiv.org/content/10.1101/2021.04.06.438634v1> (accessed on 9 September 2021).
29. Tsitsiklis, A.; Shoshana, Z.B.; Byrne, A.; Devoe, C.; Levan, S.; Rackaityte, E.; Sunshine, S.; Mick, E.; Ghale, R.; Jauregui, A.; et al. Impaired immune signaling and changes in the lung microbiome precede secondary 1 bacterial pneumonia in COVID-19. *Res. Sq.* 2021, 1, rs-3.
30. Gaibani, P.; Viciani, E.; Bartoletti, M.; Lewis, R.E.; Tonetti, T.; Lombardo, D.; Castagnetti, A.; Bovo, F.; Horna, C.S.; Ranieri, M.; et al. The lower respiratory tract microbiome of critically ill patients with COVID-19. *Sci. Rep.* 2021, 11, 10103.
31. Haiminen, N.; Utro, F.; Seabolt, E.; Parida, L. Functional profiling of COVID-19 respiratory tract microbiomes. *Sci. Rep.* 2021, 11, 6433.
32. Keely, S.; Talley, N.J.; Hansbro, P.M. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol.* 2012, 5, 7–18. Available online: www.nature.com/mi (accessed on 3 September 2020).
33. Dumas, A.; Bernard-Raichon, L.; Poquet, Y.; Lugo, G.; Neyrolles, O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. *Cell. Microbiol.* 2018, 20, e12966.
34. Dhar, D.; Mohanty, A. Gut microbiota and Covid-19 possible link and implications. *Virus Res.* 2020, 285, 198018.
35. Baud, D.; Dimopoulou Agri, V.; Gibson, G.R.; Reid, G.; Giannoni, E. Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. *Front. Public Health* 2020, 8, 186.
36. Ebrahimi, K.H. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. *FEBS Lett.* 2020, 594, 1651–1660.
37. Petersen, C.; Round, J.L. Defining dysbiosis and its influence on host immunity and disease. *Cell. Microbiol.* 2014, 16, 1024–1033.
38. Dysbiosis—Wikipedia. Available online: <https://en.wikipedia.org/wiki/Dysbiosis> (accessed on 9 September 2021).
39. Zuo, T.; Zhang, F.; Lui, G.C.; Yeoh, Y.K.; Li, A.Y.; Zhan, H.; Wan, Y.; Chung, A.C.; Cheung, C.P.; Chen, N.; et al. Alterations in gut microbiota of patients with covid-19 during time of hospitalization. *Gastroenterology* 2020, 159, 944–955.
40. Gu, S.; Chen, Y.; Wu, Z.; Chen, Y.; Gao, H.; Lv, L.; Guo, F.; Zhang, X.; Luo, R.; Huang, C.; et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. *Clin. Infect. Dis.* 2020, 71, 2669–2678.
41. Zuo, T.; Zhan, H.; Zhang, F.; Liu, Q.; Tso, E.Y.; Lui, G.C.; Chen, N.; Li, A.; Lu, W.; Chan, F.K.; et al. Alterations in fecal fungal microbiome of patients with covid-19 during time of hospitalization until discharge. *Gastroenterology* 2020, 159, 1302–1310.
42. Ren, Z.; Wang, H.; Cui, G.; Lu, H.; Wang, L.; Luo, H.; Chen, X.; Ren, H.; Sun, R.; Liu, W.; et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. *Gut* 2021, 70, 1253–1265.
43. Gou, W.; Fu, Y.; Yue, L.; Chen, G.-D.; Cai, X.; Shuai, M.; Xu, F.; Yi, X.; Chen, H.; Zhu, Y.; et al. Gut microbiota, inflammation and molecular signatures of host response to infection. *J. Genet. Genom.* 2021, in press.
44. Vighi, G.; Marcucci, F.; Sensi, L.; Di Cara, G.; Frati, F. Allergy and the gastrointestinal system. *Clin. Exp. Immunol.* 2008, 153, 3–6.
45. Hummel, S.; Veltman, K.; Cichon, C.; Sonnenborn, U.; Schmidt, M.A. Differential targeting of the E-cadherin/β-catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. *Appl. Environ. Microbiol.* 2012, 78, 1140–1147.
46. Zelaya, H.; Alvarez, S.; Kitazawa, H.; Villena, J. Respiratory antiviral immunity and immunobiotics: Beneficial effects on inflammation-coagulation interaction during influenza virus infection. *Front. Immunol.* 2016, 7, 633.
47. D’Ettorre, G.; Ceccarelli, G.; Marazzato, M.; Campagna, G.; Pinacchio, C.; Alessandri, F.; Ruberto, F.; Rossi, G.; Celani, L.; Scagnolari, C.; et al. Challenges in the management of SARS-CoV2 infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. *Front Med.* 2020, 7, 389.
48. Ceccarelli, G.; Borrazzo, C.; Pinacchio, C.; Santinelli, L.; Innocenti, G.P.; Cavallari, E.N.; Celani, L.; Marazzato, M.; Alessandri, F.; Ruberto, F.; et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. *Front Nutr.* 2021, 7,

49. Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04366089> (accessed on 13 August 2021).
50. Efficacy of *L. Plantarum* and *P. Acidilactici* in Adults with SARS-CoV-2 and COVID-19—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/study/NCT04517422> (accessed on 13 August 2021).
51. Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID-19 Infection—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04458519> (accessed on 13 August 2021).
52. Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04621071> (accessed on 13 August 2020).
53. Evaluation of the Probiotic *Lactobacillus Coryniformis* K8 on COVID-19 Prevention in Healthcare Workers—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/study/NCT04366180> (accessed on 12 August 2021).
54. Tang, H.; Bohannon, L.; Lew, M.; Jensen, D.; Jung, S.-H.; Zhao, A.; Sung, A.D.; Wischmeyer, P.E. Randomised, double-blind, placebo-controlled trial of probiotics to eliminate COVID-19 transmission in exposed household contacts (PROTECT-EHC): A Clinical trial protocol. *BMJ Open* 2021, 11, e047069.
55. Effect of *Lactobacillus* on the Microbiome of Household Contacts Exposed to COVID-19—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04399252> (accessed on 12 August 2021).
56. Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04420676> (accessed on 13 August 2021).
57. Biliński, J.; Winter, K.; Jasiński, M.; Szczeń, A.; Bilinska, N.; Mullish, B.H.; Małecka-Panas, E.; Basak, G.W. Rapid resolution of COVID-19 after faecal microbiota transplantation. *Gut* 2021, 1–2.
58. The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression with Escalating Cytokine Storm and Inflammatory Parameter—Full Text View—ClinicalTrials.gov. Available online: <https://clinicaltrials.gov/ct2/show/NCT04824222> (accessed on 16 August 2021).
59. Lopez-Leon, S.; Wegman-Ostrosky, T.; Perelman, C.; Sepulveda, R.; Rebolledo, P.A.; Cuapio, A.; Villapol, S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. *Sci. Rep.* 2021, 11, 16144.
60. Arzani, M.; Jahromi, S.R.; Ghorbani, Z.; Vahabzad, F.; Martelletti, P.; Ghaemi, A.; Sacco, S.; Togha, M. Gut-brain Axis and migraine headache: A comprehensive review. *J. Headache Pain* 2020, 21, 1–2.
61. Galland, L. The gut microbiome and the brain. *J. Med. Food.* 2014, 17, 1261–1272. Available online: <https://pubmed.ncbi.nlm.nih.gov/25402818/> (accessed on 19 June 2021).
62. Matenchuk, B.A.; Mandhane, P.J.; Kozyrskyj, A.L. Sleep, circadian rhythm, and gut microbiota. *Sleep Med. Rev.* 2020, 53, 101340. Available online: <https://pubmed.ncbi.nlm.nih.gov/32668369/> (accessed on 19 June 2021).
63. Molina-Torres, G.; Rodriguez-Arrastia, M.; Roman, P.; Labraca, M.N.S.; Cardona, D. Stress and the gut microbiota-brain axis. *Behav. Pharmacol.* 2019, 30, 187–200.
64. Ogawa, Y.; Miyoshi, C.; Obana, N.; Yajima, K.; Hotta-Hirashima, N.; Ikkyu, A.; Kanno, S.; Soga, T.; Fukuda, S.; Yanagisawa, M. Gut microbiota depletion by chronic antibiotic treatment alters the sleep/wake architecture and sleep EEG power spectra in mice. *Sci. Rep.* 2020, 10, 19554.
65. Peirce, J.M.; Alviña, K. The role of inflammation and the gut microbiome in depression and anxiety. *J. Neurosci. Res.* 2019, 97, 1223–1241.
66. Poroyko, V.A.; Carreras, A.; Khalyfa, A.; Khalyfa, A.A.; Leone, V.; Peris, E.; Almendros, I.; Gileles-Hillel, A.; Qiao, Z.; Hubert, N.; et al. Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. *Sci. Rep.* 2016, 6, 35405.
67. Smith, R.P.; Easson, C.; Lyle, S.M.; Kapoor, R.; Donnelly, C.P.; Davidson, E.J.; Parikh, E.; Lopez, J.V.; Tartar, J.L. Gut microbiome diversity is associated with sleep physiology in humans. *PLoS ONE* 2019, 14, e0222394.
68. Boehme, M.; Guzzetta, K.E.; Bastiaanssen, T.F.S.; van de Wouw, M.; Moloney, G.M.; Gual-Grau, A.; Spichak, S.; Olavarría-Ramírez, L.; Fitzgerald, P.; Morillas, E.; et al. Microbiota from young mice counteracts selective age-associated behavioral deficits. *Nat. Aging* 2021, 1, 666–676.
69. Hilpert, K.; Mikut, R. Is there a connection between gut microbiome dysbiosis occurring in COVID-19 patients and post-COVID-19 symptoms? *Front. Microbiol.* 2021, 12, 2564.
70. Vestad, B.; Ueland, T.; Lerum, T.V.; Dahl, T.B.; Holm, K.; Barratt-Due, A.; Kasine, T.; Dyrhol-Riise, A.M.; Stiksrud, B.; Tonby, K.; et al. Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19. *medRxiv* 2021. Available online: <https://www.medrxiv.org/content/10.1101/2021.07.13.21260412v1> (accessed on 9 September 2021).

Keywords

COVID-19; SARS-CoV-2; microbiome; gut microbiome; adjuvant treatment

Retrieved from <https://encyclopedia.pub/16503>